Skip to main content
Erschienen in: Infection 6/2019

08.05.2019 | Original Paper

In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections

verfasst von: Julian Marcon, Sören Schubert, Christian G. Stief, Giuseppe Magistro

Erschienen in: Infection | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To analyse the therapeutic efficacy of various phytotherapeutics and their antimicrobial compounds with regard to strain specificity and dose dependence.

Methods

A representative strain collection of 40 uropathogenic bacteria isolated from complicated and uncomplicated urinary tract infection was subjected to various virulence assays (bacterial growth, mannose-sensitive agglutination, and motility) to determine the therapeutic impact of various compounds with antimicrobial activity. We tested proanthocyanidins (PAC), d-mannose, rosemary extract (Canephron®), and isothiocyanates (Angocin®).

Results

d-mannose efficiently blocked the adhesive properties of all type 1 fimbriae-positive isolates in low concentration (0.2%), but showed no bacteriostatic effect. PAC also actively blocked agglutination, but the concentration varied considerably among isolates. Escherichia coli required the highest concentration (10%), while Enterobacter cloacae responded to low concentrations (0.1%). Allyl isothiocyanates not only impaired agglutination in all tested isolates, but also had a dramatic impact on flagella-mediated motility in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis (p < 0.001). The administration of rosemary extracts revealed a strong bacteriostatic effect in growth assays. All tested strains were strongly inhibited by the addition of 10 μg/ml or 1 μg/ml of purified rosemary extractions with the exception of Serratia marcescens. Morganella morganii responded only to 10 μg/ml.

Conclusion

Phytotherapeutics and small-molecular compounds like mannosides have the potential to become an integral part in a multi-modal treatment concept for the treatment and prevention of urinary tract infections. Their efficiency can be optimised when strain specificities and therapeutic concentrations are taken into account.
Literatur
1.
Zurück zum Zitat O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;1:1–16. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;1:1–16.
2.
Zurück zum Zitat Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.CrossRef Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.CrossRef
3.
Zurück zum Zitat Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183:S1–4.CrossRef Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183:S1–4.CrossRef
4.
Zurück zum Zitat Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, et al. Urologic diseases in America Project: analytical methods and principal findings. J Urol. 2005;173:933–7.CrossRef Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, et al. Urologic diseases in America Project: analytical methods and principal findings. J Urol. 2005;173:933–7.CrossRef
5.
Zurück zum Zitat Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653–60.CrossRef Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol. 2010;7:653–60.CrossRef
6.
Zurück zum Zitat Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32:791–801.PubMed Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014;32:791–801.PubMed
7.
Zurück zum Zitat Grabe MJ, Resman F. Antimicrobial stewardship: what we all just need to know. Eur Urol Focus. 2018;5:46–9.CrossRef Grabe MJ, Resman F. Antimicrobial stewardship: what we all just need to know. Eur Urol Focus. 2018;5:46–9.CrossRef
8.
Zurück zum Zitat Magistro G. Urological infections: “the time for change is now”. Eur Urol Focus. 2018;5:1.PubMed Magistro G. Urological infections: “the time for change is now”. Eur Urol Focus. 2018;5:1.PubMed
9.
Zurück zum Zitat Magistro G, Stief CG. Vaccine Development for urinary tract infections: where do we stand? Eur Urol Focus. 2018;5:39–41.CrossRef Magistro G, Stief CG. Vaccine Development for urinary tract infections: where do we stand? Eur Urol Focus. 2018;5:39–41.CrossRef
10.
Zurück zum Zitat Naber KG, Wagenlehner FME. Novel antibiotics in the treatment of urinary tract infections. Eur Urol Focus. 2018;5:10–2.CrossRef Naber KG, Wagenlehner FME. Novel antibiotics in the treatment of urinary tract infections. Eur Urol Focus. 2018;5:10–2.CrossRef
11.
Zurück zum Zitat Pilatz A, Veeratterapillay R, Koves B, Cai T, Bartoletti R, Wagenlehner F, et al. Update on strategies to reduce infectious complications after prostate biopsy. Eur Urol Focus. 2018;5:20–8.CrossRef Pilatz A, Veeratterapillay R, Koves B, Cai T, Bartoletti R, Wagenlehner F, et al. Update on strategies to reduce infectious complications after prostate biopsy. Eur Urol Focus. 2018;5:20–8.CrossRef
12.
Zurück zum Zitat Bonkat G, Bartoletti R, Cai T, Bruyere F, et al. EAU guidelines on urological infections. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1. Bonkat G, Bartoletti R, Cai T, Bruyere F, et al. EAU guidelines on urological infections. Edn. presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.
13.
Zurück zum Zitat Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190:1981–9.CrossRef Beerepoot MA, Geerlings SE, van Haarst EP, van Charante NM, ter Riet G. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190:1981–9.CrossRef
14.
Zurück zum Zitat Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200:1174–91.CrossRef Smith AL, Brown J, Wyman JF, Berry A, Newman DK, Stapleton AE. Treatment and prevention of recurrent lower urinary tract infections in women: a rapid review with practice recommendations. J Urol. 2018;200:1174–91.CrossRef
15.
Zurück zum Zitat Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;10:CD001321. Jepson RG, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2008;10:CD001321.
16.
Zurück zum Zitat Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:001321. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:001321.
17.
Zurück zum Zitat Magistro G, Hoffmann C, Schubert S. The salmochelin receptor IroN itself, but not salmochelin-mediated iron uptake promotes biofilm formation in extraintestinal pathogenic Escherichia coli (ExPEC). Int J Med Microbiol. 2015;305:435–45.CrossRef Magistro G, Hoffmann C, Schubert S. The salmochelin receptor IroN itself, but not salmochelin-mediated iron uptake promotes biofilm formation in extraintestinal pathogenic Escherichia coli (ExPEC). Int J Med Microbiol. 2015;305:435–45.CrossRef
18.
Zurück zum Zitat Magistro G, Magistro C, Stief CG, Schubert S. The high-pathogenicity island (HPI) promotes flagellum-mediated motility in extraintestinal pathogenic Escherichia coli. PLoS One. 2017;12:e0183950.CrossRef Magistro G, Magistro C, Stief CG, Schubert S. The high-pathogenicity island (HPI) promotes flagellum-mediated motility in extraintestinal pathogenic Escherichia coli. PLoS One. 2017;12:e0183950.CrossRef
19.
Zurück zum Zitat Schembri MA, Sokurenko EV, Klemm P. Functional flexibility of the FimH adhesin: insights from a random mutant library. Infect Immun. 2000;68:2638–46.CrossRef Schembri MA, Sokurenko EV, Klemm P. Functional flexibility of the FimH adhesin: insights from a random mutant library. Infect Immun. 2000;68:2638–46.CrossRef
20.
Zurück zum Zitat Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7:430–41.CrossRef Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol. 2010;7:430–41.CrossRef
21.
Zurück zum Zitat Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616–48.CrossRef Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev. 2012;36:616–48.CrossRef
22.
Zurück zum Zitat de Oliveira JR, de Jesus D, Figueira LW, de Oliveira FE, Pacheco Soares C, Camargo SE, et al. Biological activities of Rosmarinus officinalis L. (rosemary) extract as analyzed in microorganisms and cells. Exp Biol Med (Maywood). 2017;242:625–34.CrossRef de Oliveira JR, de Jesus D, Figueira LW, de Oliveira FE, Pacheco Soares C, Camargo SE, et al. Biological activities of Rosmarinus officinalis L. (rosemary) extract as analyzed in microorganisms and cells. Exp Biol Med (Maywood). 2017;242:625–34.CrossRef
23.
Zurück zum Zitat Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379:1835–45.CrossRef Taylor SN, Marrazzo J, Batteiger BE, Hook EW 3rd, Sena AC, Long J, et al. Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea. N Engl J Med. 2018;379:1835–45.CrossRef
24.
Zurück zum Zitat Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11:1219–36.CrossRef Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol. 2018;11:1219–36.CrossRef
25.
Zurück zum Zitat Aziminia N, Hadjipavlou M, Philippou Y, Pandian SS, Malde S, Hammadeh MY. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2018;123:753–68.CrossRef Aziminia N, Hadjipavlou M, Philippou Y, Pandian SS, Malde S, Hammadeh MY. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2018;123:753–68.CrossRef
26.
Zurück zum Zitat Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frolich R, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17:528–37.CrossRef Huttner A, Hatz C, van den Dobbelsteen G, Abbanat D, Hornacek A, Frolich R, et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect Dis. 2017;17:528–37.CrossRef
27.
Zurück zum Zitat Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3:109ra15.CrossRef Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med. 2011;3:109ra15.CrossRef
28.
Zurück zum Zitat Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010;53:8627–41.CrossRef Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem. 2010;53:8627–41.CrossRef
29.
Zurück zum Zitat Kranjcec B, Papes D, Altarac S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84.CrossRef Kranjcec B, Papes D, Altarac S. d-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84.CrossRef
30.
Zurück zum Zitat Wagenlehner FM, Abramov-Sommariva D, Holler M, Steindl H, Naber KG. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int. 2018;101:327–36.CrossRef Wagenlehner FM, Abramov-Sommariva D, Holler M, Steindl H, Naber KG. Non-antibiotic herbal therapy (BNO 1045) versus antibiotic therapy (fosfomycin trometamol) for the treatment of acute lower uncomplicated urinary tract infections in women: a double-blind, parallel-group, randomized, multicentre, non-inferiority phase III trial. Urol Int. 2018;101:327–36.CrossRef
31.
Zurück zum Zitat Sabadash MS. Canephron® N in the treatment of recurrent cystitis in women of child-bearing age: a randomised controlled study. Clin Phytosci. 2017;3:9.CrossRef Sabadash MS. Canephron® N in the treatment of recurrent cystitis in women of child-bearing age: a randomised controlled study. Clin Phytosci. 2017;3:9.CrossRef
32.
Zurück zum Zitat Albrecht U, Goos KH, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23:2415–22.CrossRef Albrecht U, Goos KH, Schneider B. A randomised, double-blind, placebo-controlled trial of a herbal medicinal product containing Tropaeoli majoris herba (Nasturtium) and Armoraciae rusticanae radix (Horseradish) for the prophylactic treatment of patients with chronically recurrent lower urinary tract infections. Curr Med Res Opin. 2007;23:2415–22.CrossRef
33.
Zurück zum Zitat Lau I, Albrecht U, Kirschner-Hermanns R. Phytotherapy in catheter-associated urinary tract infection: observational study recording the efficacy and safety of a fixed herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix. Urologe A. 2018;57:1472–80.CrossRef Lau I, Albrecht U, Kirschner-Hermanns R. Phytotherapy in catheter-associated urinary tract infection: observational study recording the efficacy and safety of a fixed herbal combination containing Tropaeoli majoris herba and Armoraciae rusticanae radix. Urologe A. 2018;57:1472–80.CrossRef
34.
Zurück zum Zitat Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci USA. 2007;104:16669–74.CrossRef Lane MC, Alteri CJ, Smith SN, Mobley HL. Expression of flagella is coincident with uropathogenic Escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci USA. 2007;104:16669–74.CrossRef
35.
Zurück zum Zitat Lane MC, Lockatell V, Monterosso G, Lamphier D, Weinert J, Hebel JR, et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun. 2005;73:7644–56.CrossRef Lane MC, Lockatell V, Monterosso G, Lamphier D, Weinert J, Hebel JR, et al. Role of motility in the colonization of uropathogenic Escherichia coli in the urinary tract. Infect Immun. 2005;73:7644–56.CrossRef
36.
Zurück zum Zitat Wright KJ, Seed PC, Hultgren SJ. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun. 2005;73:7657–68.CrossRef Wright KJ, Seed PC, Hultgren SJ. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun. 2005;73:7657–68.CrossRef
37.
Zurück zum Zitat Kaiser SJ, Mutters NT, Blessing B, Gunther F. Natural isothiocyanates express antimicrobial activity against developing and mature biofilms of Pseudomonas aeruginosa. Fitoterapia. 2017;119:57–63.CrossRef Kaiser SJ, Mutters NT, Blessing B, Gunther F. Natural isothiocyanates express antimicrobial activity against developing and mature biofilms of Pseudomonas aeruginosa. Fitoterapia. 2017;119:57–63.CrossRef
Metadaten
Titel
In vitro efficacy of phytotherapeutics suggested for prevention and therapy of urinary tract infections
verfasst von
Julian Marcon
Sören Schubert
Christian G. Stief
Giuseppe Magistro
Publikationsdatum
08.05.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 6/2019
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01315-4

Weitere Artikel der Ausgabe 6/2019

Infection 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.